1005409-06-2

Upstream product

• 111-87-5 octanol 
• 1005407-66-8 4-(n-octyloxy)-3-(trifluoromethyl)benzohydrazide 
• 1005407-63-5 4-(n-octyloxy)-3-(trifluoromethyl)benzoic acid 
• 67515-55-3 4-fluoro-3-(trifluoromethyl)benzoic acid 
• 1005407-69-1 1,1-dimethylethyl (4S)-2,2,4-trimethyl-4-[(2-{[4-(n-octyloxy)-3-(trifluoromethyl)phenyl]carbonyl}hydrazino)carbonyl]-1,3-oxazolidine-3-carboxylate 

Relevant academic research and scientific papers

Discovery of clinical candidate GSK1842799 As a selective S1P1 receptor agonist (prodrug) for multiple sclerosis

To develop effective oral treatment for multiple sclerosis (MS), we discovered a series of alkyl-substituted biaryl amino alcohols as selective S1P1 modulators. One exemplar is (S)-2-amino-2-(5-(4-(octyloxy)-3- (trifluoromethyl)phenyl)-1,3,4-th

CHEMICAL COMPOUNDS

The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, a